Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors

Shazia Bashir, Gaofeng Jiang, Ayesha Joshi, Christopher Miller, Cathleen Matrai, Anna Yemelyanova, Thomas A. Caputo, Kevin M. Holcomb, Lora Hedrick Ellenson, Divya Gupta

Research output: Contribution to journalArticlepeer-review


Objectives: Type II endometrial carcinomas-uterine carcinosarcomas or uterine malignant mesodermal mixed tumors (UMMMTs), clear cell carcinomas (UCCs), and uterine serous carcinomas (USCs)-are aggressive malignancies that present with advanced disease and have high mortality rates. PIK3CA mutations are commonly found in endometrial cancers. The objective of the study was to characterize molecular alterations in the PIK3CA gene in these tumors. Methods: A total of 84 cases (20 UMMMTs, 18 UCCs, and 46 USCs) were selected from the surgical pathology files of Weill Cornell Medical College and Johns Hopkins Hospital. The diagnoses were confirmed by gynecologic pathologists (L.H.E. and A.Y.). DNA was extracted from paraffin-embedded tissue. Polymerase chain reaction was performed for mutational analysis. All the studies were performed in accordance with approved Institutional Review Board protocols. Results: Mutations in the PIK3CA genewere identified in 3(15%)of 20 UMMMT, 3(16.7%) of 18 UCC, and 10 (21.7%) of 46 USC cases. We report novel mutations in PIK3CA in uterine carcinosarcoma. Conclusions: A significant percentage of UMMMTs, UCCs, and USCs have mutations in PIK3CA. Further investigation is needed to develop targeted therapies for these aggressive uterine cancers.

Original languageEnglish (US)
Pages (from-to)1262-1267
Number of pages6
JournalInternational Journal of Gynecological Cancer
Issue number7
StatePublished - Sep 2014


  • Carcinosarcoma
  • Clear cell
  • PIK3CA
  • Serous
  • Type II endometrial cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors'. Together they form a unique fingerprint.

Cite this